This study examined the relationship between leptin, insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3) and insulin resistance in patients with chronic kidney disease (CKD). Levels of leptin, insulin, IGF-1, IGFBP-3 and common routine parameters were measured in 45 patients (23 males and 22 females) with CKD and 45 healthy controls matched for age, gender and body mass index. IGF-1 and IGFBP-3 levels were measured using a two-site immunoradiometric assay. Leptin levels were measured using an enzyme-linked immunosorbent assay. A homeostasis model assessment computer-solved model was used to assess insulin resistance (HOMA-IR). Levels of serum leptin, insulin, IGF-1, IGFBP-3 and HOMA-IR were significantly increased in patients with CKD compared with healthy subjects, whereas fasting blood glucose was not significantly different between the two groups. In patients with CKD, the serum leptin level was significantly correlated with IGF-1, IGFBP-3 and HOMA-IR. In conclusion, this study suggests that there is an interaction between leptin, IGF-1, IGFBP-3 and insulin resistance in patients with CKD.
Introduction
Leptin was identified in 1994 by positional cloning of the ob gene that determines the development of obesity in ob/ob mice. 1 Secretion of leptin by adipocytes is stimulated by insulin, and plasma leptin correlates significantly with plasma insulin. 2 Renal clearance is the major route for leptin A Atamer, S Alisir Ecder, Z Akkus et al. Leptin, insulin resistance, IGF-1 and IGFBP-3 in chronic kidney disease excretion; 3 it has been reported that patients with chronic kidney disease have markedly elevated total serum leptin levels. 3, 4 Leptin has been shown to be implicated in the provision of normal insulin sensitivity. In the insulin-resistant state, in which higher than normal concentrations of insulin are required for a normal response, renal vasodilation effects may be lost but the stimulation of renal sodium reabsorption by insulin is maintained and even increased. Hyperinsulinaemia, which accompanies insulin resistance, is thought to play an important role in the pathogenesis of various syndromes. 5, 6 In addition, leptin exerts many potentially pro-atherogenic effects both in vitro and in vivo. 2 Leptin has a key role in energy homeostasis and there may be a link between leptin, insulin resistance and the insulin-like growth factor-1 (IGF-1) system. Experimental models have provided evidence of leptin functioning as a neuromodulator of the growth hormonereleasing factor-growth hormone-IGF axis by connecting this hormonal system with nutritional status. 7 These aspects of leptin pathophysiology have been extensively described in recent excellent reviews. 2, 5 It would seem that leptin has multiple functions in carbohydrate and lipid metabolism, the reproductive system, and inflammatory and immune reactions. 2 The IGF binding proteins (IGFBPs) play an important role in controlling the transport of IGF-1 in the circulation and its delivery to body fluids and tissues. 8 The main type of IGFBP found in serum is IGFBP-3, which is the only glycosylated IGFBP and is secreted in 41 and 38 kDa forms by several tissues. The regulation of IGFBP-3 suggests that it has a role as a growth stimulator. 5, 9 Patients with chronic kidney disease (CKD) have excess of a 29 kDa IGFBP-3 fragment in 150 kDa serum fractions and a molar excess of serum IGFBP-3 over total IGF peptides, suggesting that some serum IGFBP-3, perhaps the 29 kDa fragment in the 150 kDa serum IGFBP-3, or perhaps the 29 kDa fragment in the 150 kDa serum fractions, is unoccupied by IGF. 5, 9, 10 In recent years, the physiological role of IGFBP-3 during acute changes in plasma glucose, IGF and insulin levels has been intensively investigated. 8, 11, 12 It has been reported that leptin and IGF-1 levels are strongly influenced by body mass index, gender and age in normal subjects. 8, 11 In this study, the relationship between leptin, insulin resistance, IGFBP-3 and IGF-1 were examined in patients with CKD.
Patients and methods

PATIENTS
Patients with stage 2 or 3 CKD 13 and healthy controls matched for age, gender and body mass index (weight/height 2 ) were included in the study. Exclusion criteria were patients receiving antioxidant vitamins or iron supplements, smokers, and patients with diabetes mellitus, active hepatitis, pregnancy, immune deficiency or viral infection.
Written informed consent was obtained from all study participants. The study protocol was approved by the Ethical Committee of the Faculty of Medicine of Firat University.
MEASUREMENTS
Two to three blood samples were collected for serum creatinine assay and the true glomerular filtration rate (GFR) was determined from this according to Kidney Disease Outcomes Quality Initiative Guidelines 14 using the formula: GFR (ml/min per 1.73 m 2 ) = 186 × serum creatinine (mg/dl) -1.154 × age (years) -0.203 × 0.742 (if female).
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Serum samples were collected into Vacutainer ® tubes on the morning after an overnight fast of at least 12 h. After centrifugation, samples were frozen at -70°C on the same day until analysis.
Levels of IGF-1 and IGFBP-3 were measured using a two-site immunoradiometric assay (Diagnostic Systems Laboratories, Inc., Webster, TX, USA). For IGF-1, the sensitivity was 0.8 ng/ml and the intra-and inter-assay coefficients of variation were 3.8% and 4.9%, respectively. For IGFBP-3, the sensitivity was 0.8 ng/ml and the intra-and inter-assay coefficients of variation were 5.6% and 7.1%, respectively.
Leptin was measured by an enzymelinked immunosorbent assay (ELISA) kit (Cayman Chemicals, Ann Arbor, MI, USA). The detection limit was 0.5 ng/ml and the intra-assay coefficients of variation were 6.0% (n = 8) at 7.6 ng/ml and 2 -3% (n = 8) at 20.12 ng/ml. Serum insulin was measured using the Elecsys 1010 and Modular Analytics E170 (Roche, Indianapolis, IN, USA) electrochemiluminescence immunoassay analysers. The minimum detection limit was 0.2 µU/ml and the intra-assay coefficient of variation was 4.9%. The assays were performed in duplicate. Insulin sensitivity was assessed using a homeostasis model assessment (HOMA) computer-solved model; insulin resistance (HOMA-IR) was calculated according to the formula: (fasting insulin [µU/ml] × fasting glucose [mg/dl])/405. Common biochemical parameters were determined using standard laboratory methods according to the manufacturer's instructions.
STATISTICAL ANALYSIS
Results were expressed as means ± SD. Statistical analysis was performed using the SPSS ® 10.01 for Windows ® program (SPSS Inc., Chicago, IL, USA). Differences between groups were compared using the unpaired Student's t-test or the Mann-Whitney nonparametric test as appropriate. Pearson's correlation analyses were performed to evaluate relationships between the various parameters studied. A P-value < 0.05 was considered to be statistically significant.
Results
The clinical and laboratory characteristics of the study participants are given in Table 1 . A total of 45 stage 2 and 3 CKD patients and 45 healthy matched controls were included in the study. The causes of CKD in the patients were primary glomerular disease in 20 patients, autosomal dominant polycystic kidney disease in 15 patients and unknown in 10 patients. The GFR values in the CKD patient group ranged between 35 and 70 ml/min per 1.73 m 2 .
Levels of serum leptin, insulin, IGF-1, IGFBP-3 and HOMA-IR were significantly increased in patients with CKD compared with healthy subjects (P < 0.001). Serum urea and creatinine levels were significantly higher and glomerular filtration rates were significantly lower in patients with CKD than in healthy subjects (P < 0.001). Fasting blood glucose was not significantly different between the two groups.
In patients with CKD, the serum leptin level significantly correlated with IGF-1 (r = 0.821, P < 0.001), IGFBP-3 (r = 0.694, P < 0.001) and HOMA-IR (r = 0.795, P < 0.001) ( Fig. 1) .
Discussion
In the present study, patients with CKD were found to have significantly higher levels of serum leptin, IGF-1 and IGFBP-3 than healthy subjects. The growth hormonereleasing factor-growth hormone-IGF axis and leptin have both been found to play an Leptin, insulin resistance, IGF-1 and IGFBP-3 in chronic kidney disease important role in their regulation. 6 The aetiology of increased levels of serum leptin and IGFBPs in patients with CKD is thought to be multifactorial; reported data suggest involvement of a decreased glomerular filtration rate, 15 cardiovascular events 2, 16 and hyperinsulinaemia. 17 It is possible that leptin itself is not atherogenic, with the changes in leptin levels simply reflecting changes in insulin resistance and hyperinsulinaemia. 2 High IGF-1 concentrations in serum are due, in part, to high levels of IGFBP and these high levels would also be consistent with resistance at the IGF-1 receptor level. 10 In a study of patients on peritoneal dialysis, serum leptin and IGF-1 levels were found to be higher than in those undergoing conservative therapy or haemodialysis. 6 In CKD subjects, hyperleptinaemia has been suggested to be associated with peripheral DNA damage, 3 anaemia 18 and IGFs 6 as well as cardiovascular events. 16 Secretion of leptin is greatly influenced by various hormonal factors. Short-term hyperinsulinaemia probably has no effect on leptin secretion, whereas long-term hyperinsulinaemia or insulin resistance causes an increase in leptin levels. 19 The hyperinsulinaemia that accompanies insulin resistance may be implicated in the development of pathological states, such as coronary heart disease, type 2 diabetes mellitus, and metabolic syndrome and its associated diseases. 5 Hyperinsulinaemia may also induce sympathetic nervous system activation, renal sodium retention and changes in cation transport, which may contribute to the development of hypertension. 20 In addition, the finding in the present study of an association between insulin resistance and an increased serum leptin level is consistent with the literature. 5, 11, 17 In the present study, serum leptin levels were significantly correlated with the serum IGF-1 level and HOMA-IR in patients with CKD. In a report by Cordido et al., 6 serum leptin and IGF-1 levels were significantly correlated in patients with CKD, suggesting an important physiological link between the growth hormone-releasing factor-growth hormone-IGF axis and leptin. Consistent with this, serum levels of IGFBP-2 and, to a lesser extent IGFBP-1, correlated inversely and significantly with height standard deviation scores in children with CKD, implying that these two IGFBPs contributed to growth failure in these children. 8, 9 IGF-1 is a mitogenic polypeptide that stimulates cellular proliferation and differentiation. Its function is modulated by six binding proteins with high affinity. 12, 21 The biological effects of IGF-1 are regulated by IGFBP-3, which is responsible for its transport in the blood. 8 It has also been reported that increased IGFBP levels may play an important role in decreased IGF-1 bioavailability and are probably a key factor in the development of growth hormone/IGF-1 resistance in CKD. 22 IGFBP-3 fragments of 30 kDa have a binding affinity 10 times lower than intact IGFBP-3 for IGF-1 and may, thus, enhance IGF bioavailability. 10 An excess of IGFBPs in CKD would, therefore, be able to bind more IGF molecules and might act as inhibitors of IGF, reducing its bioactivity. 6 There are, therefore, at least two possible explanations for growth retardation in CKD patients: (a) high levels of IGFBP inducing IGF sequestration and lowering IGF availability, or (b) IGF-1 receptor resistance. 10 In conclusion, the present study demonstrated that there is an association between serum levels of leptin and IGF-1, IGFBP-3 and HOMA-IR in patients with CKD.
